Governments are increasing domestic investment in tuberculosis (TB) programmes as international health financing faces growing pressure, with new figures showing that more than two million people who developed the disease in 2025 were never diagnosed or officially reported.
The World Health Organization (WHO), in its 2026 Global Tuberculosis Report released on 12 November, says domestic funding for TB prevention and treatment increased by 14 per cent, reaching US$5.6 billion between 2024 and 2025.
The increase has helped cushion a decline in international financing of a similar magnitude, highlighting the growing responsibility of national governments to sustain essential health services amid tightening global development budgets.
Despite these financial challenges, the global TB response continues to record improvements. An estimated 10.6 million people developed the disease in 2025, while 1.1 million died, reflecting a continued decline in the number of infections and deaths.
TB-related deaths have fallen by 35 per cent since 2015, while treatment has saved an estimated 86 million lives since 2000. This progress means the world has achieved the mortality milestone under WHO’s End TB Strategy, although five years behind its original 2025 deadline.
However, the reduction in new infections remains significantly slower than anticipated. Between 2015 and 2025, the global TB incidence rate declined by only 14 per cent, against a target reduction of 50 per cent.
TB also remains the leading cause of death from a single infectious agent, underscoring the distance countries must cover before eliminating the epidemic.
WHO Director-General Dr Tedros Adhanom Ghebreyesus said governments had made important efforts to protect TB programmes by increasing domestic allocations despite reductions in international assistance.
He warned, however, that more than one million people continue to die annually from a disease that can be prevented and treated, calling for stronger financing, wider access to healthcare and faster development of new diagnostic and treatment technologies.
Africa records progress as regional inequalities persist
The global burden of TB remains concentrated in 30 countries, which accounted for 88 per cent of all people who developed the disease in 2025.
Progress has varied considerably across WHO regions. Between 2015 and 2025, TB incidence declined by 42 per cent in the European Region and 30 per cent in the African Region.
South-East Asia recorded an 18 per cent reduction, while the Eastern Mediterranean Region achieved a 6.6 per cent decline. The Western Pacific Region recorded no overall change, while the Americas experienced a fifth consecutive year of increasing incidence, reaching levels 13 per cent higher than those recorded in 2015.
WHO attributes these differences partly to variations in population-level risk factors, healthcare infrastructure, access to diagnostic and treatment services, and the consistency of government investment.
For Africa, the 30 per cent decline represents substantial progress, but the remaining burden highlights the need to strengthen health systems and ensure that more people can access testing and treatment before the disease advances.
Millions remain outside the treatment system
Despite improvements in global TB outcomes, significant gaps remain in identifying people with the disease and connecting them to appropriate care.
Of the estimated 10.6 million people who developed TB in 2025, only 8.4 million were diagnosed. This leaves approximately 2.2 million people either undiagnosed or unreported, creating challenges for disease surveillance and efforts to interrupt transmission.
Access to modern diagnostic technology is another concern. Only 59 per cent of newly diagnosed patients were tested using WHO-recommended rapid diagnostic tests, falling considerably short of the 100 per cent coverage target set for 2027.
Rapid testing is important in identifying TB infections and supporting timely treatment decisions, particularly in settings where delays in diagnosis can contribute to continued transmission.
Drug-resistant TB presents an additional challenge. WHO estimates that 370,000 people developed rifampicin-resistant tuberculosis in 2025, yet only 42 per cent received treatment.
There are, however, encouraging developments in the management of drug-resistant infections. The proportion of treated patients receiving the WHO-recommended six-month treatment regimen increased from 18 per cent in 2024 to 42 per cent in 2025.
The improvement points to growing adoption of shorter treatment options, although the low overall treatment coverage means many affected people are still not receiving the care they need.
Research funding threatens the development of new tools
Beyond financing existing programmes, WHO is highlighting the need for greater investment in research to accelerate the development of improved TB vaccines, diagnostic technologies and treatments.
Global TB research funding stood at US$1.2 billion in 2023, less than one-quarter of the US$5 billion annual investment target set for 2027.
The funding gap threatens efforts to develop and make available new tools that could improve prevention, shorten treatment periods and help countries respond more effectively to drug-resistant infections.
WHO is urging governments and international partners to strengthen political commitment, protect domestic health budgets and expand access to preventive interventions, rapid diagnosis and effective treatment.
The organisation is also calling for increased investment in research and innovation, warning that current progress remains insufficient to put the world on course to end the TB epidemic.
As international health financing becomes increasingly uncertain, the rise in domestic investment offers an important opportunity for countries to protect existing gains. However, the millions still missing from diagnosis and treatment demonstrate that increased spending must translate into accessible services and better health outcomes.


